Company: ARTL
Filing Date: 2025-07-11
Form Type: S-1
Source: 0001640334-25-001190
Chunk: 20

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-07-11
Form: S-1
Chunk 20
---
 litigation brought by or against us;                                                         |
| · | regulatory developments and the decisions of regulatory authorities as to the approval or rejection of new or modified products;                                                |
| · | changes in the amounts that we spend to develop, acquire or license new products, technologies or businesses;                                                                   |
| · | changes in our expenditures to promote our product candidates;                                                                                                                  |
| · | our sale or proposed sale, or the sale by our significant stockholders, of our shares or other securities in the future;                                                        |
| · | changes in key personnel;                                                                                                                                                       |
| · | success or failure of our research and development projects or those of our competitors;                                                                                        |
| · | the trading volume of our shares; and                                                                                                                                           |
| · | general economic and market conditions and other factors, including factors unrelated to our operating performance.                                                             |

| 10 |

These factors and any corresponding price fluctuations may materially and adversely affect the market price of our shares and result in substantial losses being incurred by our investors. In the past, following periods of market volatility, public company stockholders have often instituted securities class action litigation. If we were involved in securities litigation, it could impose a substantial cost upon us and divert the resources and attention of our management from our business.

We are obligated to use commercially reasonable efforts to invest $250,000 of the net proceeds from the Private Placement to purchase Solana, a cryptocurrency, the price of which has been, and will likely continue to be, highly volatile.

Under the Purchase Agreement, we are obligated to use commercially reasonable efforts to use $250,000 of the net proceeds from the Private Placement to purchase Solana, a cryptocurrency. Solana is a highly volatile asset. Solana does not pay interest, but if management determines to stake the Solana tokens in treasury, certain rewards can be earned on Solana. The ability to generate a return on investment from the purchase of Solana will depend on whether there is appreciation in the value of Solana. Future fluctuations in Solana’s trading prices may result in our converting Solana into cash with a value substantially below the value at which such Solana was purchased.

Any Solana we purchase may be less liquid than our existing cash and cash equivalents and may not be able to serve as a source of liquidity for us to the same extent as cash and cash equivalents.

Historically, the crypto markets have been characterized by: significant volatility in price, limited liquidity and trading volumes compared to sovereign currencies markets; relative anonymity; a developing regulatory landscape; potential susceptibility